Overview

Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes

Status:
Terminated

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

This study will look at the skin accumulation of vildagliptin and its two major metabolites, LAY151 and LAF237-O-Glucuronide, after vildagliptin 50 mg given orally twice a day for 10 days in both healthy volunteers and patients with type 2 diabetes.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Novartis

Treatments:

Vildagliptin